Provided by Tiger Trade Technology Pte. Ltd.

Nektar Therapeutics

72.14
+0.76001.06%
Volume:120.65K
Turnover:8.68M
Market Cap:2.46B
PE:-11.15
High:72.73
Open:70.41
Low:70.00
Close:71.38
52wk High:109.00
52wk Low:27.87
Shares:34.14M
Float Shares:28.53M
Volume Ratio:0.47
T/O Rate:0.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.4680
EPS(LYR):-9.7254
ROE:-35.75%
ROA:-12.54%
PB:2.73
PE(LYR):-7.42

Loading ...

Peer‑Reviewed REZOLVE‑AD Phase 2b Data Could Be A Game Changer For Nektar Therapeutics (NKTR)

Simply Wall St.
·
Aug 31

Nektar Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Reuters
·
Aug 29

Nektar Grants Inducement Equity Awards to New Hires, Including Options Priced at USD 74.53

Reuters
·
Aug 29

Nektar Therapeutics - Rezolve-Ad Study Meets All Primary and Key Secondary Endpoints for Rezpegaldesleukin 24 ΜG/Kg Q2w

THOMSON REUTERS
·
Aug 25

Nektar Therapeutics : JP Morgan Resumes Coverage with Neutral Rating; Target Price $65

THOMSON REUTERS
·
Aug 21

Nektar Therapeutics’ Earnings Call Highlights Rezpeg Momentum

TIPRANKS
·
Aug 21

Piper Sandler Remains a Buy on Nektar Therapeutics (NKTR)

TIPRANKS
·
Aug 20

Is Phase III Rezpegaldesleukin And Cash Runway Progress Altering The Investment Case For Nektar Therapeutics (NKTR)?

Simply Wall St.
·
Aug 14

Nektar Therapeutics Falls on Quarterly Revenue Miss

Reuters
·
Aug 14

Nektar Therapeutics Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

Earnings Flash (NKTR) Nektar Therapeutics Posts Q2 Loss $1.23 Per Share, vs. FactSet Est of $1.97 Loss

MT Newswires Live
·
Aug 14

Nektar Q2 FY26 Net Loss Narrows to $40.62 Million; Revenue Falls 9.35% to $10.1 Million

Reuters
·
Aug 14

Nektar Q2 2026 Earnings: Phase 3 Spending Rises as Cash and Investments Top $1 Billion

TradingKey
·
Aug 14

Nektar Therapeutics Q2 EPS $(1.23) Beats $(2.00) Estimate, Sales $10.131M Miss $10.425M Estimate

Benzinga Earnings
·
Aug 14

Nektar Therapeutics Q2 EPS USD -1.23

THOMSON REUTERS
·
Aug 14

Earning Preview: Nektar Therapeutics revenue expected to decrease by 3.91%, and institutional views are bullish

Earnings Agent
·
Aug 06

Nektar Therapeutics to Report Q2 Results After U.S. Market Close, Hosts Conference Call

Reuters
·
Jul 29

Is Nektar Therapeutics (NKTR) Undervalued On Its Phase 3 Rezpegaldesleukin Launch?

Simply Wall St.
·
Jul 28

Nektar Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Reuters
·
Jul 25

Nektar Grants 36,000 Inducement Stock Options Priced at $64.84 Per Share

Reuters
·
Jul 25